Genmab

	11/5 17:20 af JKY_VH	Ja det er den da kkjoel 7.5, sorry:-)
	11/5 17:17 af E L	not that long ago that Bluebird was the markets favourite, now they are changing their CAR-t deal with BMS to get some cash... (link)
	11/5 17:08 af kkjoel	Den er vist fra forleden, JKY - har dem til at have løftet til $30 den 07.05 - svarende til 2067 ved dagens kurs 6,89.
	11/5 17:05 af E L	lol, that is the ugliest cup i have ever seen TheNote ;-)
	11/5 17:05 af JKY_VH	Genmab får løftet kursmålet til 2045 kr. fra 1950 kr. af finanshuset Suntrust Robinson, der fastholder anbefalingen køb.
	11/5 17:04 af E L	also great for Genmab employees if they can exercise some warrants later this week
	11/5 17:01 af nohope	Pis - så er der stadig 110 til sommerferien...
	11/5 17:00 af Helge Larsen/PI-redaktør	Luk i 1.890. :-D
	11/5 17:00 af Skyggen	Mange tak Solsen :-) og tak for en rigtig fin Q&A ;-)
	11/5 17:00 af kkjoel	Det er helt fint, Helge - de har travlt med at fiorhandle deal på plads.. så kan godt vente.
	11/5 16:58 af Helge Larsen/PI-redaktør	kkjoel...Var lige ved at poste det. Fik en venlig sms om at tiden var overskredet.
	11/5 16:56 af Solsen	TheNote har haft et par steger, der pegede på 2100 som top ;-)
	11/5 16:55 af Skyggen	Er der nogen Ta Eller andre streger der følger med i dette område ????‍♂️
	11/5 16:54 af kkjoel	Ja, vi er - faretruende vel, i nohopes øjne - tæt på 1900 ;-) Noget MÅ vi da kunne ikke-håbe på!
	11/5 16:50 af kkjoel	Helge - kan godt se mit spørgsmål vedr. vigtigheden af US market var marginalt ift. de andre mere essentielle antistof-teknologi spørgsmål... håber dog du får plads til at stille det næste gang.. måske ovenpå en deal ;-)
	11/5 16:49 af Solsen	Mon vi kan lukke i 1900. Så er der kun en dag til 2000 ;-). Hvis vi kan holde tempoet ,,,
	11/5 16:44 af kkjoel	Sidder her med tilbageholdt åndedræt.. det man har venter på i nogle år sker for øjnene af en. En art déjà vu :-)
	11/5 16:19 af nohope	Something that could control the cytokinstorm.
	11/5 16:18 af nohope	Would be great if they could pick something as a generalist against vira for the future pandemics - but Covid-19 should be gone long time before.
	11/5 16:17 af nohope	Covid-19
	11/5 16:17 af nohope	I sure don´t hope it is Genmab with AB who is going to save us from
	11/5 16:10 af Solsen	Very interesting that Genmab are involved. But I think its all over before they are able to have anything ready.
	11/5 16:09 af E L	i don't want to read too much into it, but curious ;-)
	11/5 16:08 af E L	i am curious now on "Genmab's next generation AB technologies for making better COVID-19 antibody therapeutics.."

	11/5 16:07 af Solsen	Thats the reason Iam not sure about the future. But again here Genmab was wise not to put more money in something that could be too toxic.
	11/5 16:05 af Sukkeralf	The warheads on ADCT´s ADCs are much more potent but as you say safety is the big issue. Ohad Hammer did not like ADCTs their approch
	11/5 16:05 af Solsen	Yes sukker its crowded.
	11/5 16:04 af Solsen	JW was clever not to disclose which small molecule he preferred ;-)
	11/5 16:04 af Sukkeralf	there have been a lot of focus on next generation BTK inhibitors - if ot not with ibrutinib then maybe one of those
	11/5 16:03 af Solsen	Its a good option on cami-t. I think the antibody conjugate are much better than SGENs Adcetris, which sold for $164 mln in Q120 in north america. BUT safety could be an issue.
	11/5 16:03 af E L	@Bulder it seems he already knows what the next epco trial will look like...
	11/5 16:01 af kkjoel	Åh nej, det hedder: super hungry ;-)
	11/5 16:00 af kkjoel	and hungry maybe...
	11/5 16:00 af Sukkeralf	Such a strong engine they have - again most BP must look at that and be envious
	11/5 15:59 af Bulder	yes and the combo opportunities with small molecules and epco
	11/5 15:57 af E L	nice to hear tfrom BioNtech & CureVac "more to come"
	11/5 15:57 af kkjoel	Yes, tak Helge.. super exiting ;-)
	11/5 15:57 af Legolas23	Tak for et godt Q$A. Skarpe spørgsmål. Jeg sad i bilen og fulgte sporadisk med :-)
	11/5 15:55 af bikube	Sådan et event her er godt for kursen - ny ATH
	11/5 15:55 af GeorgeBest	Tak for din insats Helge, uden den ville denne fantastiske mulighed ikke eksistrere. Flot.
	11/5 15:54 af E L	i assume they created the option during that decision to not develop with ADC; it will probably come at a price when they want back in?
	11/5 15:54 af Helge Larsen/PI-redaktør	Tusinde tak for alle de skarpe spørgsmål. Desværre tillod tiden ikke at alle blev postet.
	11/5 15:51 af Sukkeralf	I thought they have rejected that option a while ago
	11/5 15:51 af henrik48	Tusind tak til kompetente spørgere og moderator for en glimrende Q&A
	11/5 15:45 af E L	I did not realise Genmab could up the stakes in Camidanlumab. nice option
	11/5 14:50 af Helge Larsen/PI-redaktør	10 minutter til Q&A. :-)
	11/5 10:58 af Bulder	So according to Landgren guidelines say ok to sc in all indications.
	11/5 10:58 af GeorgeBest	AlphaValue raises target price on Genmab to 1902, but keeps reduce rating
	11/5 10:56 af Bulder	off line = off label
	11/5 10:55 af Bulder	I think the connection between listing and guidelines is that if a drug is on the compendia listing it can be used off line. If it is in the guidelines it can be used in a way described in the guidelines.